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1.  Introduction  
 
Article 5.1 of Council Decision 2005/387/JHA (1) (hereinafter the ‘Decision’) stipulates 
that ‘Where Europol and the EMCDDA, or the Council, acting by a majority of its 
members, consider that the information provided by the Member State on a new 
psychoactive substance merits the collection of further information, this information 
shall be collated and presented by Europol and the EMCDDA in the form of a Joint 
Report (hereinafter the ‘Joint Report’).’ The Joint Report shall be submitted to the 
Council, the European Medicines Agency (EMEA) and the Commission. 
 
In December 2006, Europol and the EMCDDA examined the available information on 
a new psychoactive substance, 1-benzylpiperazine (BZP) through a joint assessment 
based upon the following criteria: 
 
1. the amount of the material seized; 
2. evidence of organised crime involvement; 
3. evidence of international trafficking; 
4. analogy with better-studied compounds; 
5. evidence of the potential for further (rapid) spread; and 
6. evidence of cases of serious intoxication or fatalities. 
 
The EMCDDA and Europol agreed that the information collected on BZP satisfies at 
least criteria 1, 3, 5 and 6. The two organisations, therefore, concluded that sufficient 
information has been accumulated to merit the production of a Joint Report on BZP 
as stipulated by Article 5.1 of the Decision. 
 
2. Information collection process 
 
In compliance with the provisions of the Decision, on 12 December 2006 Europol and 
the EMCDDA launched a procedure for collection of further information on BZP, in 
order to prepare the Joint Report. The information was collected mainly through the 
networks in the Member States – the Europol national units (ENUs) and Reitox 
national focal points (NFPs). In addition, the EMEA collected information through the 
Member States’ national competent authorities (NCAs) responsible for medicinal 
products. The information collection process was largely concluded by 23 January 
2007; however, additional information and clarifications from some Member States 
were received during the following four weeks. 
 
Europol asked the ENUs to provide information on: 
− the level of production of BZP in their country; 
− the level of distribution of BZP in their country; 
− the level of trafficking in their country, both for internal, transit or export 
purposes; 
− the number of seizures of BZP in their country, the total amount of the 
seizures, country of origin, details on the tablets and logos, including photos; 
− the role of organised crime, or criminal groups, in the production, distribution 
and trafficking of BZP in their country; 
− any known aspect of violence and/or money laundering relating to the 
production and trafficking of BZP. 
 
Europol received responses from twenty-three Member States (2).  
 
                                                          
(1) OJ L 127, 20.5.2005, p. 32; 
(2) Two Member States, Greece and Italy did not provide information to Europol.  
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According to Article 5.3, EMEA asked the Member States’ national competent 
authorities (NCA) responsible for human and veterinary medicinal products to provide 
information on whether: 
− the new psychoactive substance BZP has obtained a marketing authorisation; 
− the new psychoactive substance BZP is the subject of an application for a 
marketing authorisation; 
− a marketing authorisation that had been granted in respect of the new 
psychoactive substance BZP has been suspended. 
 
Furthermore, in anticipation of Article 7.3 of the Decision in relation to the 
manufacturing of medicinal products in the European Union, the EMEA, in 
consultation with the EMCDDA, requested whether the new psychoactive substance 
BZP is used to manufacture a medicinal product: 
− which has been granted a marketing authorisation; or, 
− for which an application has been made for a marketing authorisation; or, 
− for which a marketing authorisation has been suspended by a competent 
authority. 
 
Twenty-two Member States and two Third States (3) replied to the EMEA’s request.  
 
The rest of the information included in the Joint Report was collected by the 
EMCDDA through a structured questionnaire from the Reitox NFPs. The EMCDDA 
received replies from all twenty-seven Member States and Norway. A specific 
information request on whether or not BZP is under assessment by the UN system 
was also made to the World Health Organization (see section 3.5). Furthermore, an 
extensive literature review was carried out by the EMCDDA. To facilitate the reading 
of the report, the full references of the quoted scientific articles are in general not 
included in the text; however, a list of the main information sources is annexed 
(Annex 1). 
 
Thus, information included in sections 3.2.1, 3.3 and 3.6 of the Joint Report was 
provided by Europol, while the EMCDDA provided information included in sections 
3.1, 3.2.2, 3.4, 3.5, 3.6, 3.7 and 3.8. The information included in sections 3.8 (partly), 
4.1, 4.2 and 4.3 was provided by the EMEA. The conclusions and recommendations 
of the Joint Report were prepared and agreed by the two responsible organisations – 
the EMCDDA and Europol – in consultation with the EMEA. 
 
3.  Information requested by Article 5.2 of the Decision 
 
The order and titles of subsections 3.1 to 3.8 and section 4 below are exactly as they 
appear in Article 5.2(a) to (h) and Article 5.3(a) to (c) of the Decision. Moreover, all 
sections are cross-referenced with those set down in the Decision. 
 
3.1 Chemical and physical description, including the name under which the 
new psychoactive substance is known – Article 5.2(a) of the Decision 
 
Chemical description and names 
1-benzylpiperazine is a psychoactive substance which belongs to a group of aryl-
substituted piperazines that includes, amongst others, 1-(3-chlorophenyl)piperazine 
(mCPP), m-trifluoromethylphenylpiperazine (TFMPP), 1-(4-methoxyphenyl)-
piperazine (pMeOPP), p-fluorophenylpiperazine (pFPP), dibenzylpiperazine (DBZP), 
                                                          
(3)  Austria, Cyprus, the Czech Republic, Denmark, Estonia, Finland, France, Germany, Hungary, Ireland, Italy, 
Latvia, Lithuania, Malta, the Netherlands, Poland, Portugal, Romania, Slovenia, Spain, Sweden and the 
UK; and Norway and Liechtenstein. 
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1-(3,4-methylenedioxybenzyl)piperazine (MDBP), etc. The latter two together with 
BZP form the subgroup of benzylpiperazines, whereas the remaining could be 
described as phenylpiperazines. Alternative chemical names of BZP are N-
benzylpiperazine (4) and 1-benzyl-1,4-diazacyclohexane. 
 
1-benzylpiperazine is better known by one of its codenames – BZP, which is an 
abbreviation for benzylpiperazine. Another, less used codename is A2 supposedly 
after the alternative chemical name 1-benzyl-1,4-diazacyclohexane. However, as use 
of codenames could be confusing, they should be used only for initial orientation (5). 
Some of the users’ and brand names by which BZP is known in the EU Member 
States are included in subsection 3.8.2 of the Report.  
 




Molecular formula:  C11-H16-N2
 
Molecular weight: 176.26 Daltons (base); 249.19 Daltons (2HCl) 
 
Identification and analytical profile 
Chemical Abstracts Service (CAS) registry numbers of BZP: 2759-28-6 (base); 5321-
63-1 (2HCl). 
 
Colour screening tests results: BZP does not react to Marquis (6) and Scott’s; it has a 
positive reaction to Nitroprusside.  
 
Mass spectral data for BZP (m/z): 91 (base peak); 134, 56, 176, 65.  
(Detailed analytical profiles of BZP and other piperazines are available at the 
EMCDDA.) 
 
Physical description (general) 
1-benzylpiperazine is available as either base or hydrochloride salt (2HCL). The base 
form is a pale, slightly yellowish-green liquid; the hydrochloride salt is a white solid. 
The base form of BZP is a corrosive product which can cause burns; the 
hydrochloride salt is an irritant to eyes, respiratory system and skin. Further 
indications of the health risks associated with BZP can be found in subsection 3.4.  
 
BZP is commercially widely available from chemical suppliers on the Internet (7) 
where it can be purchased in bulk. Furthermore, Internet sites targeting recreational 
                                                          
(4) International Union of Pure and Applied Chemistry (IUPAC) name.  
(5)  For example, A2 is used also as a brand name, furthermore, the code name A2 has been reportedly 
mentioned on the Internet in relation to another chemical – 6-triflouro-N-benzyl-methyl piperazine. 
(6)  According to erowid.org – BZP gives no colour change, but it causes the reagent to fizz (‘looks like when 
you pour hydrogen peroxide on a cut’). 
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drug users offer shipments of BZP powder in various quantities – 1g, 5g, 10g up to f. 
e. 200g. The purity of BZP offered on the Internet is supposedly very high (99% - 
99.8%).  
 
A more detailed description of the physical form of the BZP seizures in the European 
Union Member States can be found in subsection 3.2 below. Description of various 
BZP-containing ‘party pills’, ‘legal highs’ etc., sold by online shops can be found in 
subsections 3.2 and 3.8.2. A full account of the available images of seizures and 
collected samples is annexed (Annex 2). 
 
3.2  Information on the frequency, circumstances and/or quantities in which 
a new psychoactive substance is encountered, and information on the 
means and methods of manufacture of the new psychoactive substance 
– Article 5.2(b) of the Decision 
3.2.1 Information provided to Europol 
 
The level of production, distribution and trafficking 
As BZP is legally available via the internet and the chemical industry, processing 
activities by organised crime are limited to tableting or encapsulating. 
 
Eight Member States reported seizures of BZP to Europol. Denmark, Finland, 
France, Germany, Malta, Spain and Sweden reported minor seizures, ranging from a 
seizure of one capsule in France to approximately 170 tablets seized in two incidents 
in Malta. In Finland, 21 tablets were seized on six occasions. One of these seizures, 
in August 2006, related to a parcel arriving from the United Kingdom with tablets 
branded as ‘JAX’ and ‘flying Angel’ originating from internet sale. Sweden made 25 
seizures of BZP in 1999, in powder and capsules, often mixed with amphetamine or 
MDMA. In 2006, seven seizures of tablets were made. The United Kingdom, reported 
four seizures of powder, totalling 995 mg, five seizures of nine capsules in total, and 
91 seizures of tablets, including a significant seizure of 64,900 tablets. In the latter 
case, tablets had a ‘Mitsubishi’ logo, which suggests that they were intended to be 
sold as ‘ecstasy’.  
 
Two Member States reported on legal importations: in Ireland, limited quantities were 
imported, mainly from New Zealand, and distributed in local ‘smart-shops’. Germany 
reported on importations from France to a German company, for research and 
analysis purposes, totalling 15 times 100 ml and 13 times 25 ml.  
 
Germany also reported on an incident in August 2005, in which a small-scale 
laboratory was found with the seizure of 62 ml liquid 1-benzylpiperazine and 20.18 
grams of benzylpiperazinedihydrochloride in powder form.   
 
Apart from a single seizure of 64,900 tablets in the United Kingdom, no Member 
State provided information that suggests large-scale processing of, and/or trafficking 
in BZP. The Irish, German and Finnish contributions indicate legitimate distribution in 
Ireland; small-scale research and analysis use in Germany and availability on the 
internet via United Kingdom based internet sites. 
 
Fifteen Member States: Austria, Belgium, Cyprus, the Czech Republic, Estonia, 
Hungary, Ireland, Latvia, Lithuania, Luxembourg, the Netherlands, Poland, Portugal, 
                                                                                                                                                                      
(7)  For example, chemical suppliers such as Sigma-Aldrich (UK), Fluka Chemie GmbH, Buchs (Switzerland), 




the Slovakia and Slovenia reported to Europol that they had made no seizures of 
BZP (8). 
3.2.2  Information provided to the EMCDDA 
 
Thirteen Member States and one Third State reported BZP detections (9) to the 
EMCDDA, as follows: Austria, Belgium, Denmark, Germany, Greece, Ireland, Spain, 
Finland, France, Malta, the Netherlands, Sweden and the United Kingdom; and 
Norway. The reported BZP detections refer to the following physical forms: tablets of 
various colours, weight, diameter, thickness, shape, with or without a logo and/or 
markings – found in Denmark, Finland, France (10), Germany, Ireland, Malta, the 
Netherlands, Portugal, Spain, Sweden and the United Kingdom; powders of various 
colours – found in Austria, Belgium, Denmark, Finland, Germany, Malta, Netherlands 
and Sweden; various mono-and bi-coloured capsules – found in Denmark, Finland, 
France, Greece, Ireland, the Netherlands, Sweden and the United Kingdom;  paste 
and pulp – found in Portugal and Sweden respectively; and yellowish clear liquid – 
found uniquely in Germany.  
 
Seizures 
Most of the Member States reported small seizures, which varied from a single 
seizure in Belgium and Greece (a small quantity of powder and three capsules 
respectively), to few seizures of 1 to 10 units (tablets or capsules) or small quantities 
of powder (Denmark, France, Germany, Finland, Ireland, Malta, Portugal and Spain). 
Malta also reported two slightly bigger seizures in tablet form (see Europol above).  
 
The Netherlands Forensic Institute (NFI) examines all Dutch drug seizures, except 
for Amsterdam. In 2006, the NFI examined more than 13,000 ‘exhibits’ (11) of which 
approximately 2,000 concerned tablets. About 200 of these, i.e. 10% of the illegal 
tablet seizures, concerned tablets containing piperazine derivates (12). However, in 
total, only 11 of all the seizures contained BZP – 3 consisting of tablets and 8 
consisting of powders.  
 
The United Kingdom reported seizures by the Police in England, Scotland and 
Northern Ireland. Apart from the large quantity of 64,900 tablets seized from a car in 
London (also reported to Europol, see above), two other major cases involved 5,311 
tablets seized in Strathclyde, Scotland in December 2006 as well as a seizure of 
2,068 tablets. The latter case involved also a small quantity of powder and two 
capsules. Most tablets also contained TFMPP and most carried either a ‘Mitsubishi’ 
or a ‘Smiley Face’ logo. Occasionally BZP was found as an adulterant in MDMA 
tablets. BZP tablets sometimes contained DBZP – possibly a synthetic impurity. 
 
In general, it was not uncommon that BZP in the seized units was in combination with 
other substances of the piperazines group, most notably, TFMPP (Denmark, France, 
Greece, Ireland, the Netherlands, and the United Kingdom), but also MeOPP 
(Denmark and the Netherlands), mCPP (the Netherlands), DBZP (the Netherlands 
and the United Kingdom). Furthermore, various other substances were also 
encountered in combination with BZP – tripelennamine (Azarone; an antihistamine) 
                                                          
(8) However, Belgium, Ireland and the Netherlands did report small seizures of BZP to the EMCDDA. 
(9) ‘Detections’ is an all encompassing term, which may include seizures and/or collected and/or biological 
samples. 
(10)  All tablets reported by France were seized in New Caledonia (Oceania), no further information on 
quantities has been reported.  
(11)  The data are from seizures in the Netherlands during 2006, only part of the December seizures are 
missing.  
(12)  These include 1-(3-chlorophenyl)piperazine (mCPP), for more information on this substance, see Europol-
EMCDDA Joint Report on mCPP (14409/05 CORDROGUE 73). 
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(Denmark and France), cocaine (Malta), caffeine (the Netherlands and Sweden, see 
below), 2-phenylethylamine (2-PEA) (the Netherlands), MDMA (the United Kingdom), 
etc.  
 
The Swedish data 
The most complete data sets on BZP detections between 2000 and 2006 are 
available from the Swedish Police, Customs and the National Board of Forensic 
Medicine – Department of Forensic Chemistry. These data are described in detail 
since they may illustrate the dynamics of the developing BZP market.   
 
Since the first identification of BZP in 1999, the National Laboratory of Forensic 
Science which carries out analyses on seizures made by the Police has analysed 
118 seizures (13). The seizures have mainly been detected in the southern part of the 
country, but a few seizures have also been made in the north. The first seizure in 
1999 consisted of a powder and since then this has been a common form. Since the 
year 2000, 45 powder seizures totalling 655g have been made. The powders were of 
white colour as well as different shades of beige and yellow; sometimes pure BZP, 
sometimes mixed with other substances. Between 2002 and 2004, 305 capsules 
were found in 23 seizures. Seven different types of capsules were analysed – 
uncoloured, red, white/red, green and turquoise some of them having a mixture of 
various kinds of substances. The first tablet containing BZP was seized in 2003. 
Between 2005 and 2006 nine further seizures of tablets were made. The 197 seized 
tablets were of seven different types and colours – white, white mixed, light brown, 
brown mixed and pink. Some were pure BZP and some were mixed with other 
substances.  
 
In many of the units (tablets or powders) containing BZP, combinations with other 
psychoactive substances were found. In 2001 ketamine was found in one mixture, 
TFMPP was found in seizures from 2002 and 2003. For a period of three years 
caffeine seems to have been the most common BZP adulterant, this combination 
having been detected between 2002 and 2005. In 2006, combinations with N-methyl-
N-benzylpiperazine were analysed as well as with less common substances such as 
sildenafil, phenazone and chavicine (a constituent of black pepper).  
 
The Swedish Customs made their first two seizures of BZP in 2002. Both seizures 
consisted of powders. Since then two more seizures of powders have taken place in 
2004 and 2006. The powders were white with no other ingredients. Other powders 
involved in the same case were dextromethorphan (DXM), TFMPP and cocaine. The 
latest seizure of BZP powder by the Customs was of 23kg, together with parts of a 
tableting machine. 
 
In 2003, the first seizure of tablets was found consisting of one white tablet together 
with steroids and tablets containing ephedrine. In 2006, there were four seizures 
totalling 2,251 tablets of three different kinds, red, pink and white with different logos 
such as ‘LOVE’ and ‘PULSE III’. In 99% of all tablets caffeine was detected and in 8 
tablets TFMPP (which is a controlled substance in Sweden). 
 
A fatal case associated with BZP in Sweden as well as the identifications of BZP in 
biological samples (14) reported from Malta, Sweden and the United Kingdom are 
discussed in details in subsection 3.4.1. 
 
                                                          
(13)  For the year 1999 no specific data is available; furthermore the figures from 1999 and 2000 may not be 
fully reliable due to a change in reporting system. Data described in the text are from 2000 onwards. 
(14) Biological (human) samples, e.g. body fluids (urine, blood), tissues, hair, etc.  
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Collected samples, availability and content of BZP products 
In addition to the seizures and the identifications in biological samples, three Member 
States (Austria, Ireland and the Netherlands) reported also collected samples (15).  In 
November 2006, in Vienna a small amount of BZP powder was analysed in the 
framework of the pilot pill-testing project ‘ChEckiT!’. Since 2003, the following 
samples were delivered to the Dutch Drugs Information and Monitoring System 
(DIMS) – six powders (three in 2003 and three in 2004) and 13 ecstasy-like tablets in 
2006. In Ireland, samples were taken from a ‘head shop’ and analysed by the 
Forensic Science Laboratory, as follows: 56 pink capsules containing BZP and MPP 
(methylphenylpiperazine); 100 capsules containing BZP and TFMPP, some of the 
capsules were white, some pink and white and some orange; 6 red capsules 
containing BZP and caffeine; 2 round blue half-scored tablets which had a ‘lightening 
flash’ design imprinted on them – all tablets contained BZP only.  
 
Despite the various seizures on the illicit drugs market described above, it seems that 
the main source of BZP-containing products for recreational users is the Internet 
where it is been widely sold and aggressively marketed by a number of (supposedly 
United Kingdom-based) online shops (16). Such products are also sold in the so-
called ‘head shops’ in Ireland and in the United Kingdom as well as at ‘legal high’ 
stalls at clubs and festivals. BZP-containing products are often marketed under the 
umbrella terms ‘legal highs’ or ‘party pills’ (with various brand names, see subsection 
3.8.2 below) and are sometimes misrepresented as ‘natural’ or ‘herbal’ products.  
 
In order to identify the active ingredients contained in such products, their quantities,  
and to determine how the actual contents match the listed ingredients, a team from 
St. George’s University of London purchased and analysed different tablets and 
capsules from three major internet suppliers. The study found that of the 26 tablets 
and capsules screened, 23 contained one or more of the following piperazines: BZP, 
TFMPP, pFPP, pMPP, mCPP and DBZP. BZP was present in 21 of the 23 
piperazine-containing tablets/capsules. Additional ingredients were nicotineamide in 
capsules and caffeine in tablets. The most common combination both in the capsules 
and in the tablets was BZP with TFMPP. The quantification of BZP and TFMPP in 
tablets and capsules (n=20) gave a mean BZP of 65mg and TFMPP of 22mg. 
However, the range varied widely between 28–133mg BZP and 4–72mg TFMPP. 
The content stated on the packaging for BZP ranged from 105mg to 200mg, and for 
TFMPP from 50mg to 75 mg. (Source Analytical Unit, St. George’s University of 
London, United Kingdom) 
 
3.3 Information on the involvement of (international) organised crime in the 
manufacture or trafficking of the new psychoactive substance – Article 
5.2(c) of the Decision 
 
The United Kingdom provided Europol with information indicating the involvement of 
organised crime in the acquisition and tableting of, and/or trafficking in, BZP. None of 
these data source the tablets’ origin, whilst the use of logos indicates that they are 
sold in the user environment as ecstasy. 
 
Money laundering aspects 
 
No information was received on money laundering related to the production and/or 
trafficking of BZP. 
 
                                                          
(15) Samples collected and analysed for monitoring, research or prevention/harm reduction purposes. 
(16) For example, http://www.everyonedoesit.co.uk/, http://www.youknowit.com/, http://www.spiritualhigh.co.uk/, 
http://www.legal-highs-shop.co.uk/, http://www.wellcoolstuff.com/, etc. 
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Violence in connection with production, wholesale and distribution 
 
No information was received on incidents of violence in connection with production, 
wholesale and/or distribution of BZP. 
 
 
3.4 A first indication of the risks associated with the new psychoactive 
substance, including the health and social risks, and of the 
characteristics of users – Article 5.2(d) of the Decision 
3.4.1 First indications of health risks 
 
Background information 
BZP is a central nervous system stimulant. BZP has a complex action working 
directly and indirectly on central monoamine receptors. Pharmacological studies 
indicate a central serotoninomimetic action which involves serotonin re-uptake 
inhibition and 5-HT1 receptor agonistic effects. Furthermore, it is said that BZP 
triggers the release of dopamine and noradrenaline and inhibits their synaptic re-
uptake.  
 
The peripheral actions of BZP on alpha-2 adrenoceptors mediate reflex tachycardia 
and hypertension. The pharmacokinetics and human metabolism of BZP are 
incompletely understood, although BZP is known to be poorly metabolised and is 
largely excreted unchanged by the kidneys (Gee at al., 2005). There is a possibility 
that BZP may interact with certain medicinal products and lead to the development of 
a serotonin syndrome. 
 
Studies in humans compared the physiological and subjective effects of BZP with 
those of amphetamine, and suggested that these are substantially similar, but that 
BZP has approximately one-tenth (10%) of the potency of dexamphetamine. A 
double blind study (Campbell et al., 1973) found that former amphetamine addicts 
were unable to distinguish between equipotent doses of BZP and amphetamine. The 
former amphetamine addicts tested with both BZP and dexamphetamine scored BZP 
higher than dexamphetamine. A more recent study (Bauman et al., 2005) has shown 
that a combination of BZP with TFMPP mimics the molecular mechanism and some 
of the effects of MDMA (ecstasy).   
 
In a recent study, BZP functioned as an effective reinforcer in rhesus monkeys 
(Fantegrossi et al., 2005). BZP maintained i.v. self-administration above rates 
observed for saline, comparable with cocaine. When evaluated in monkeys trained to 
discriminate amphetamine from saline, BZP had full amphetamine-like effects. These 
findings suggest the psychomotor stimulant-like effects of BZP. Previously this has 
been shown in mice (Miller et al., 1971), rats (Oberlander et al., 1979; Kosóczky et 
al., 1978) and humans (Campbell et al., 1973; Bye et al., 1973). Moreover, the 
results of Fantegrossi et al. (2005) support drug discrimination experiments indicating 
stimulant-like effects of BZP in rats (Jones et al., 1980) and extend them by 
demonstrating similar effects in primates. These results suggest that BZP may have 
abuse liability of the amphetamine type. 
 
A 100mg dose of BZP is said to have effects of between 6–8 hours duration. In 
doses between 75 and 150mg BZP is reported to produce arousal, euphoria, 
wakefulness, improved vigilance and feeling of wellbeing. Users, however, also 
describe various negative experiences such as anxiety, vomiting, headache, 
difficulties to sleep, palpitations, confusion, collapse and seizures. Side-effects may 
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include dilated pupils, dryness of the mouth, and problems with urine retention. BZP 
is also said to produce a severe hangover after the drug effect wears off. Some of 
those symptoms reportedly may persist for up to 24 hours. 
 
In New Zealand, where the longer history and the legal status of the phenomenon 
allowed it to be better studied, the 2006 National household survey of legal party pill 
use (17) (2,010 respondents, aged 13–45 years old) provides some insight into the 
harms and problems related to the use of party pills. The psychological problems 
most often experienced from legal party pill use were ‘trouble sleeping’ (50.4%), ‘loss 
of energy’ (18.4%), ‘strange thoughts’ (15.6%), ‘mood swings’ (14.8%), ‘confusion’ 
(12.1%) and ‘irritability’ (11.4%). The physical problems most often experienced from 
legal party pill use were ‘poor appetite’ (41.1%), ‘hot/cold flushes’ (30.6%), ‘heavy 
sweating’ (23.4%), ‘stomach pains/nausea’ (22.2%), ‘headaches’ (21.9%) and 
‘tremors and shakes’ (18.4%) (18). 
 
BZP appears to have a narrow safety margin when used recreationally, possibly 
because of intrinsic pharmacodynamic properties, self-dosing variability, or genetic 
polymorphism. Those with seizure disorders or coronary disease should avoid BZP 
as should those taking prescription sympathomimetics or anticholinergics. Co-
ingestion with MDMA or amphetamine should also be cautioned against (Gee at al., 
2005). 
 
The risk associated with the use of BZP in humans has not been determined. In 
terms of toxicity, little is known about the long- or short-term effects of BZP. In New 
Zealand, where BZP has been recreationally used since 2000, there have been a 
number of reported incidents of users suffering serious side-effects from legal party 
pills. Some of these incidents have resulted in medical emergencies and hospital 
admissions. A recent New Zealand Medical Journal article described 80 BZP-related 
Emergency Department admissions occurring at Christchurch Hospital over a six-
month period in 2005. The authors concluded that BZP can cause unpredictable and 
serious toxicity in some people. The authors advise that those with seizure disorders 
or coronary disease should avoid using BZP, as should those taking certain 
prescription medicines (Gee et al., 2005). Legal party pill use has been linked with 
one case of drug psychosis requiring admittance to a Christchurch acute psychiatric 
facility (Saunders, 2005).  
 
Given the physical forms in which BZP is available and the intended users, in the 
great majority of the cases the substance is taken orally (ingested). However, since 
BZP in powder form is also widely available, it cannot be excluded that the substance 
is also snorted or injected by users who usually snort or inject ecstasy. However, no 
such case has been reported to the EMCDDA so far. According to the above-
mentioned 2006 National household survey in New Zealand, nearly all (98.8%) of 
those who had used legal party pills in the previous year typically ‘swallowed’ them; 
only one user (0.6%) reported they typically injected them. The intravenous use of 
BZP has also been reported by some drug and alcohol practitioners working in New 
Zealand. 
 
The European data 
Most of the data available from the Member States at the time of the preparation of 
this report show the availability and the use of BZP in Europe, rather than providing 
conclusive evidence about the risks associated with it. The most valuable information 
                                                          
(17)  Legal party pills are products containing either BZP and/or TFMPP along with herbal stimulants such as 
guarana and black pepper see subsection 3.8.2. 
(18)  All New Zealand data in this section are from 2006 National household survey of legal party pill use 
(Wilkins et al., 2006).  
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about the health risks related to BZP is a detailed report from the UK which described 
toxicologically confirmed (and quantified) and clinically observed intoxications 
involving BZP as the only consumed psychoactive substance. Evidence on specific 
social risks associated with BZP is limited.  
  
The first post-mortem identification involving BZP was reported from Sweden as early 
as 1999. Subsequently, Malta, Sweden and the United Kingdom have reported 
biological (blood or urine) samples, conclusively demonstrating BZP consumption 
and providing some insight into the various combinations of piperazines used.  
 
In 1999, the Swedish National Board of Forensic Medicine, Department of Forensic 
Chemistry, found the presence of BZP in a sample of femoral blood (1.7mg/L) in the 
autopsy of a 22-year-old male. MDMA, MDA and THC were all present in that case 
(Wikstrom et al., 2004). Further search of the records of the Department of Forensic 
Chemistry revealed that a second post mortem identification of BZP in an autopsy 
case of a 24-year-old male was made in 2002. Amphetamine and THC were also 
present in this case. However, the extent to which BZP is implicated in these deaths 
is not known. Furthermore, a report from the University Hospital in Zurich, 
Switzerland, details the death of a young female user. The exact role of BZP in this 
case is also not known, as additional risk behaviour as well as other psychoactive 
substances such as MDMA are reported to have been involved (Balmelli et al., 
2001). 
 
In the course of the information collection for the preparation of this report, the United 
Kingdom reported that BZP was also found in post mortem analyses of two death 
cases due to road accidents. These cases, involving 26- and 32-year-old males, 
occurred in England (West Midlands) and Wales respectively. In both cases BZP was 
quantified in blood and urine samples, but a number of other psychoactive 
substances were also found e.g. cannabinoids, cocaine, ephedrine, MDMA, 
ketamine, amphetamine, diltiazem and ethanol. Therefore, it could be assumed with 
a high level of certainty that the possible role of BZP in these cases was negligible 
(19).   
 
The Swedish National Board of Forensic Medicine, Department of Forensic 
Chemistry, reported the analyses of 15 blood samples and 50 urine samples from 
living individuals (ante-mortem) which showed the presence of BZP. The blood 
samples were analysed between 2000 and 2006 and the urine samples between 
1999 and 2006. The blood samples were all from individuals arrested by the Police, 
whereas the urine samples were taken also from prison inmates.  Amphetamine, 
methamphetamine, THC and benzodiazepines were other substances identified in 
these samples. The circumstances of the Police arrests were often petty drug 
offences, but also traffic violations. Geographically, the tested individuals came from 
12 different cities in the middle and southern parts of Sweden. The age range of the 
tested individuals is 15–51 (mean around 25) with males being disproportionately 
represented.  
 
Between March and December 2006, BZP was detected ante-mortem in fourteen 
urine samples analysed at the Toxicology Laboratory of the Malta General Hospital 
(some of these cases had been referred by the emergency department). In three of 
the cases, BZP was the only substance present; in two other cases BZP was present 
in combination with MDMA only, whereas in all other cases more than two 
psychoactive substances were detected e.g. MDMA, cocaine, opiates, ketamine, 
                                                          
(19)  In New Zealand, it has been argued  (Candor Trust –  road safety group) that party pills enhance driving 
and are, in fact, ‘saving lives’ because they provide a legal and safer alternative to controlled stimulants 
such as methamphetamine.  
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benzodiazepines, alcohol and THC. Similarly, the UK reported that between May and 
December 2006, BZP was found in urine samples of five males in England (three of 
the samples were quantified). In two of the cases the age of the individuals is not 
known, but the other three are reported to have been 14, 26 and 32. One of the 
cases involved BZP only, whereas in the remaining four TFMPP was also present, as 
well as MDMA and methadone and MDMA and quinine in two of the cases.  
 
In May 2006, during a weekend seven patients aged between 18 and 23 presented 
themselves simultaneously at the emergency department at St. Thomas’ Hospital 
London. All of the patients were at a single club in south London and had ingested 
tablets, which they believed to be ecstasy or amphetamine. The tablets were 
purchased from the same dealer. The numbers of tablets ingested per patient ranged 
from 4 to 9. Two patients had collapsed in the club with witnessed self-terminating 
grand mal seizures. On arrival at the hospital, five of the patients had evidence of 
sympathomimetic toxidrome with dilated pupils, anxiety, agitation and tachycardia. 
The patients were admitted for observation and treated with i.v. fluids and per os/i.v. 
benzodiazepines as required. Serum samples were collected from four patients and 
were analysed by the Toxicology Service at St. George’s University of London. After 
eight hours of observation none of the patients had evidence of ongoing toxicity and 
all were discharged. All samples were negative for alcohol and controlled drugs, 
including amphetamines, cocaine, opiates, methadone and benzodiazepines. 
However, BZP was detected in all four samples. It should be noted that the serum 
concentrations in three of the cases (1.9, 1.9, and 2.5 mg/L) exceeded those 
reportedly measured in the Swedish autopsy case (see above). (Source: Analytical 
Unit, St. George’s University of London, Guy’s St. Thomas’ Poison Unit, London 
United Kingdom.) 
  
Furthermore, in the United Kingdom there has been an alleged drug facilitated sexual 
assault case in which BZP and 1-(4-methoxyphenyl)piperazine (pMeOPP) were 
detected in a urine sample.  The concerned individual declared to have taken pills 
called ‘PEP Love’. The empty pill container was labelled as containing ‘a piperazine 
blend’ and supplied by www.spiritualhigh.co.uk. No further details about the case are 
available.   
3.4.2 Characteristic of users 
 
BZP tablets are in the great majority of the cases sold/bought as ‘party pills’ where 
the content is more or less correctly marked (this is not always the case with the 
quantity). However, from the appearance of some of the seizures (f. e. in the United 
Kingdom), it could be assumed that on some occasions BZP may be sold on the 
illegal market as the popular drug ecstasy (20). Therefore, although there have been 
no specific studies of the characteristics of BZP users in Europe, it can be assumed 
that they are the same as those of the well-studied ecstasy-using population. In 
summary, this is predominantly a youth phenomenon, in particular of 15- to 24-year-
olds, with rates of drug use higher in males than in females, predominantly from 
urban areas, who frequent clubs, discos and dance events.   
 
In New Zealand, the 2006 ‘National household survey of legal party pill use’  provides 
some national population statistics on the prevalence and patterns of legal party pill 
use (2,010 respondents, aged 13–45 years). One in five (20.3%) of the sample had 
ever tried legal party pills, and one in seven (15.3%) had used legal party pills in the 
                                                          
(20)  Although a report from Malta and some internet accounts (lyceaum.org) suggest that BZP powder may be 





preceding 12 months. Levels of last year use of legal party pills were highest among 
the 18- to 24-year-old age range with 33.9% of 18- to 19-year-olds and 38.0% of 20- 
to 24-year-olds having used legal party pills in the preceding year. Males were more 
likely than females to have used legal party pills in the previous year in a number of 
age groups including among 13- to 14-year-olds (4.4% vs. 0%), 20- to 24-year-olds 
(48.5% vs. 27.9%), 30- to 34-year-olds (15.4% vs. 6.6%), 35- to 39-year-olds (10.7% 
vs. 2.2%) and 40- to 45-year-olds (7.6% vs. 2.5%). 
 
3.5 Information on whether or not the new substance is currently under 
assessment, or has been under assessment by the UN system – Article 
5.2(e) of the Decision 
 
The World Health Organisation (WHO) is the specialised UN Agency designated for 
the evaluation of the medical, scientific and public health aspects of psychoactive 
substances under the 1961 and 1971 UN Conventions.  
 
The WHO informed the EMCDDA that 1-benzylpiperazine (BZP) is currently not 
under assessment and has not been under assessment by the UN system. 
 
3.6 The date of notification on the Reporting Form of the new psychoactive 
substance to the EMCDDA or to Europol – Article 5.2(f) of the Decision 
 
The first official EMCDDA–Europol record of BZP (reported as ‘A2’) is from late 1999 
when Sweden reported a BZP seizure (powder) which was made in September 1999. 
The analysis was carried out by the National Laboratory of Forensic Science. At that 
time, Sweden reported that 25 seizures (21) and one post-mortem identification of 
BZP had been made in 1999. At a later stage, the Swedish NFP completed the 
information, adding that in 1999 there were four more analyses of urine samples of 
living individuals (ante-mortem) – two of them showing that BZP was the only 
substance used (22). Nevertheless, the first formal notification of BZP to the EMCDDA 
through a reporting form is of 27 October 2003 from the Belgian NFP. It concerns a 
single seizure of 3.8g of white powder made by the Police in Turnhout in September 
of that same year.  
 
At the end of 1999, BZP was added to the list of new psychoactive substances 
monitored by Europol and the EMCDDA via the Early Warning System (EWS) and 
further information about detections in seizures, biological and collected samples was 
amassed by the two responsible organisations and the Member States. Between 
2000 and 2006, information about BZP identifications, together with analytical details 
and background information has been exchanged on various occasions between 
Europol, the EMCDDA and the Member States. The Commission and the EMEA 
were kept duly informed. In 2006, the number of notifications to the EMCDDA and/or 
Europol of encounters of BZP and, in particular, of recent intoxications, increased, 
thus prompting the production of this Joint Report. 
 
                                                          
(21) These figures may not be fully reliable as in 2000 there was a change in the reporting system in Sweden.   
(22) In the information collection process for the preparation of this report, the EMCDDA was informed that in 
1999 BZP was also seized in Norway. At that time, however, Norway was not a member of the EMCDDA 
and, therefore, not reporting via the Early Warning System.     
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3.7 Information on whether or not the new psychoactive substance is 
already subject to control measures at national level in a Member State 
– Article 5.2(g) of the Decision 
 
In twenty-two Member States and in Norway, 1-benzylpiperazine is not controlled 
under the terms of the 1961 or 1971 UN Conventions. 
 
Five Member States – Belgium, Denmark, Greece, Malta and Sweden – control BZP 
under drug control or equivalent legislation. In Belgium, as of 18 October 2004, BZP 
is regulated by the Royal Decree on Psychotropic Substances (23). In Denmark, on 
the recommendation of the National Health Board, the Minister for the Interior and 
Health amended the Executive Order on Euphoric Substances, adding 1-
benzylpiperazine to the list of controlled substances. The Executive Order entered 
into force on 3 December 2005. Consequently, BZP may only be used for medical or 
scientific purposes. In Greece, the substance BZP is classified in Table A (24) of Law 
1729/87 and is, therefore, subject to the same control measures that apply to, for 
example, cannabis, heroin, LSD or MDMA. In Malta, as of 16 June 2006, BZP is 
controlled as a psychotropic substance under the Medical and Kindred Profession 
Ordinance (Chapter 3 – Section A). Sweden controls BZP under the Act on the 
Prohibition of Certain Goods Dangerous to Health; the regulation entered into force 
on 1 March 2003.  
 
Furthermore, the Italian Ministry of Health has recently started a procedure to bring 
BZP under control as a narcotic drug (Table 1). As provided by Law 309/90, the 
responsible Unit (Central Drug Office – Ufficio Centrale Stupefacenti) has submitted 
the proposal to the High Council of Health for an opinion. 
 
Two Member States – the Netherlands and Spain – apply control measures to BZP 
under their medicines legislation. In the Netherlands, BZP is considered to be a 
medicinal product and is, therefore, controlled under medicinal products legislation. 
In Spain, BZP is not classified as a drug but it is considered a chemical substance 
with medicinal features (stimulant and other). Consequently, it is controlled by the 
Law 25/1990 on medicinal products that controls all chemical substances with 
medicinal features. The EMCDDA has been informed that in 2006, the Estonian 
State Medicines Agency under the Ministry of Social Affairs has considered 
introducing control measures related to BZP.   
 
In March 2004, New Zealand’s Expert Advisory Committee on Drugs considered BZP 
and related substances. The Committee concluded that there was insufficient 
evidence to control these substances and recommended further research. However, 
as of July 2005 BZP was classified in a newly created category – Class D of the 1975 
Misuse of Drugs Act – restricting the sale and supply to persons who are 18 years of 
age or older. Similarly, in Ireland, despite the fact that BZP is not controlled as a 
psychoactive substance under the national drug control legislation or medicines 
regulations, in the so-called ‘head shops’ it is sold only to persons 18 years and 
older. 
 
In the USA, BZP was temporarily placed into Schedule I of the Controlled 
Substances Act (CSA) on 20 September 2002. On 18 March 2004, the Drug 
                                                          
(23)  Recent information suggests that control measures in one Member State may have certain repercussions 
on the availability of the product in the other Member States. For example, the EMCDDA was informed by 
the UK EWS correspondent that Thermo Fisher (ex Fisher Scientific) withdrew BZP from retail sale in the 
UK, supposedly after it was controlled in Belgium in late 2006.  
 
(24)  Handling of the substances included in Table A is an exclusive right of the state. 
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Enforcement Administration (DEA), US Department of Justice published a Final Rule 
in the Federal Register, permanently placing BZP in Schedule I of the CSA. BZP is a 
controlled substance in all states of Australia as well as in Japan where it is listed as 
a narcotic in the Narcotics and Psychotropics Control Law. 
 
As of 1 January 2007, BZP is included in the Prohibited List of the World Anti-doping 
Code as a stimulant substance prohibited in competition.  
 
3.8 Further information – Article 5.2(h) of the Decision 
3.8.1 The chemical precursors that are known to have been used for the 
manufacture of the substance 
 
BZP is a piperazine derivative, and an entirely synthetic substance. Neither BZP nor 
other piperazines are derived or ‘synthesised’ from the pepper plant. As stated earlier 
in this report (see section 3.2) BZP is legally widely available and there seems to be 
no need for illicit production. The DEA (2001) states that the chemical process to 
manufacture BZP is straightforward; therefore it can be manufactured without 
sophisticated laboratory equipment (standard equipment is nonetheless needed). 
However, BZP and piperazines (in general), are relatively inexpensive, and when 
clandestinely processed in Europe and the United States, they are usually purchased 
in bulk (in powder or liquid form) through the internet and/or from chemical suppliers 
and then processed into tablets  
 
However, it should be noted that a description of synthetic methods for BZP is readily 
available on the internet and in the specialised literature (25). The synthesis of BZP is 
based on the reaction of piperazine monohydrochloride (26) with benzyl chloride (27), 
both of which are relatively simple, easily available chemicals (precursors). This 
method could be adapted to create other benzylpiperazines. Also, it seems possible 
that dibenzylpiperazine (DBZP), a chemical closely related to BZP, could form as an 
impurity in the synthetic process. Furthermore, notes could be found on the internet 
showing how to convert piperazine citrate (the form used commercially as an 
anthelminthic) to piperazine monohydrochloride.  
3.8.2 The mode and scope of the established or expected use of the new 
substance 
 
The recreational use of BZP is reported to have first occurred in late 1996 in 
California. According to the DEA, after 2000 in the United States there has been a 
growing popularity of BZP, evidenced by the ‘increasing encounters of this substance 
by law enforcement officials’. In its Final Rule (2004) on the placement of BZP into 
Schedule I of the CSA, the DEA states that ‘BZP has increasingly been found in 
similar venues as the popular club drug MDMA (ecstasy). BZP often in combination 
with TFMPP, is sold as MDMA, promoted as an alternative to MDMA and is targeted 
to youth population. BZP (alone or in combination with TFMPP) has been 
encountered in powder and tablet form and sold on the Internet.’      
 
                                                          
(25) For example, J. Cymerman Craig, W. P. Rogers, and M. E. Tate, Australian J. Chem., 9, 397 (1956); R. 
Baltzly, J. S. Buck, E. Lorz, and W. Schon, J. Am. Chem. Soc., 66, 263 (1944); R. E. Lutz and N. H. 
Shearer, J. Org. Chem., 12, 771 (1947).  
(26)  Piperazine monohydrochloride is the primary precursor; from the viewpoint of a possible precursor 
control, it would be necessary to specify 'piperazine and its salts' since the various forms of 
piperazine (salts and/or hydrates) could all be converted to piperazine monohydrochloride without too 
much difficulty. 
(27)  Benzyl chloride is reportedly a carcinogenic substance. 
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In New Zealand, ‘herbal’ party pills have been sold without regulation since 2000 and 
since mid-2004, party pills have become widely available and are commonly used by 
young people. They have been marketed as ‘herbal’ and ‘safe’. Conservative 
estimates from 2005 suggest that approximately 150,000 doses of party pills/legal 
herbal highs are sold in New Zealand every month. These products contain BZP 
and/or TFMPP along with herbal stimulants such as guarana and black pepper. The 
individual characteristics of different legal party pill products seem to be achieved 
largely by varying the ratio and quantities of BZP and TFMPP to achieve the desired 
level of stimulant versus empathic and hallucinogenic effects. 
 
BZP was first notified via the EMCDDA-Europol EWS back in 1999, but the 
emergence of piperazines as recreational drugs with potential for rapid spread in 
Europe lay relatively latent until the second half of 2004, when various mCPP tablets 
appeared in the majority of the Member States, often designed to look like ecstasy 
and almost always sold/bought as the popular drug ecstasy. Approximately at the 
same time, BZP-containing products started to be aggressively marketed in some 
European Union Member States (for example, in printed media and in various 
designated shops in the United Kingdom and Ireland) and on the internet as a legal 
alternative to ecstasy (legal E or legal X), but clearly specified as a piperazine 
products, often erroneously or intentionally misrepresented as a ‘natural’ or ‘herbal’. 
Brand names include, Pep pills (Pep original, Pep X, Pep twisted, Pep love, etc); 
Funk pills (Flying Angel, Twisted), JAX; Red Eye Frog (Californian Sunrise, 
Strawberry Fields); Triple X (XXX), Efx, etc.  
 
The popularity and legality of BZP and BZP-containing products have resulted in 
numerous users’ names, many of which are in fact brand names. According to some 
researchers (Gee et al., 2005) there are more than 120 brand names/synonyms. BZP 
may be sold as ecstasy under the street name of ‘Legal E’ or ‘Legal X’, XTC, Herbal 
ecstasy, etc. Beside ‘herbal party pills’, ‘party pills’ and ‘Nemesis’ in New Zealand, 
BZP containing products are available as Frenzy, Bliss, Charge, etc. A2, BZP, 
’benzylpiperazine’, ‘piperazine’ are all used.  
 
Although not as highly regarded by the users as, for example, ecstasy, the marked 
psychoactive effects of BZP – stimulant or ecstasy-like when combined with TFMPP 
– may be contributing to its popularity. For users who are aware of the fact that they 
consume BZP, i.e. those who purchased it as such, it seems that this drug may have 
certain appeal. This specific demand or market for BZP-containing products may be, 
however, also due to their legal status and accessibility. Furthermore, the perceived 
safety of BZP is fostered by the fact that the products are often sold by designated 
retailers or in specialised shops, where the content is visibly stated, rather than on 
the street. All these factors may contribute to the establishment of BZP as a 
recreational drug of choice in its own right. Currently, BZP seems to be the most 
popular piperazine derivate in Europe. However, the Dutch DIMS reports that at the 
moment BZP seems to be less frequently used in the Netherlands than mCPP. The 
Swedish Poison Information Center reported that in the period from 2000 to 2003, 
there had been 15 information requests regarding BZP; however, there had been no 
requests between 2004 and 2006, which may be due to the change in the control 
status of BZP. A French outreach investigator reported a particular interest for this 
substance in the context of a festival in the south of France, where the users reported 
that they wanted to distinguish themselves from traditional synthetic drug users. 
 
Little or no information is available on the price of BZP on the illegal drugs market in 
the Member States.  
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3.8.3 Other use of the new psychoactive substance and the extent of such 
use, the risks associated with this use of the new psychoactive 
substance, including the health and social risks. 
 
BZP was first synthesised in 1944 by Wellcome Research Laboratories, United 
Kingdom as a potential anthelmintic (to treat intestinal parasitic worms) for livestock 
but not used as it was found to be relatively ineffective and caused adverse effects 
such as seizures in mammals. In fact, apart from the parent compound – piperazine 
– the piperazine derivatives, which were originally intended as potential anthelminthic 
agents in humans and animals were actually never licensed (28). Benzyl derivatives 
were further investigated in the 1970’s but trials were stopped when it was found out 
that they had stimulant properties and a potential for misuse.  
 
In anticipation of Article 7.3 of the Decision in relation to the manufacturing of 
medicinal products in the European Union, the EMEA, in consultation with the 
EMCDDA, requested whether the new psychoactive substance BZP is used to 
manufacture a medicinal product: 
− which has been granted a marketing authorisation; or, 
− for which an application has been made for a marketing authorisation; or, 
− for which a marketing authorisation has been suspended by a competent 
authority 
 
Furthermore, a preliminary search by the EMCDDA revealed that BZP could 
(theoretically) be used in the synthesis of at least four active substances – Cetirizine, 
Meclozine, Oxatomide and Trimetazidine (INNs). Therefore, in order to confirm the 
situation in reality, the EMEA requested information on whether or not BZP is used in 
the manufacture of medicinal products containing these active substances. In the 
event of a positive response for any of the four substances, information was 
requested on: 
− the active substance; 
− the manufacturer of the active substance; 
− the invented name of the medicinal product; 
− the marketing authorisation holder (MAH) for the medicinal product. 
 
The above questions were addressed to both human and veterinary agencies. 
Twenty-two Member States and two Third States, which replied to the EMEA’s 
question answered ‘no’ or ‘not known’.  
 
Furthermore, a literature search revealed that the active substance Piberaline (Rec. 
INN) (chemical name: 1-(phenylmethyl)-4-(2-pyridinylcarbonyl)-piperazine or 1-
benzyl-4-picolinoylpiperazine) had been synthesised in the 1980’s by EGYT Hungary 
(29), registered and limitedly marketed as an anti-depressant under the name 
Trelibet®. Although, it seems that Trelibet® was later withdrawn (1985), the 
information available at the EMCDDA indicated that the active substance Piberaline 
metabolises to BZP and that BZP is an intermediate in its synthesis. Therefore, the 
EMEA also asked the Member States to check if there was more information about 
the current use of this active substance. 
 
Twelve Member States (Cyprus, the Czech Republic, Denmark, Germany, Hungary, 
Ireland, Latvia, Lithuania, Poland, Romania, Slovenia and Spain) and one Third State 
                                                          
(28) Only, diethylcarbamazine (DEC) (4-methyl-N,N-bis(4-methylpiperazin-2-yl)-piperazine-1-carboxamide) 
which is effective against certain parasitic filarial worms (human lymphatic filariasis) has found a significant 
place in human therapeutics. 
(29)  Now EGIS Pharmaceuticals. 
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(Norway) which replied to the EMEA’s question gave a ‘negative response’. Eight 
Member States (Austria, Estonia, Finland, France, Malta, the Netherlands, Sweden 
and the United Kingdom) and one Third State (Liechtenstein) did not answer the 
question.  
 
The Swedish NFP reported that in 2005–2006 two companies had a permission to 
use BZP – one of them is a pharmaceutical company which reportedly uses the 
substance for the development of new potential medicinal products. In Denmark, it is 
reported that very small quantities of BZP are used in few certified laboratories under 
supervision of the Danish Medicines Agency. 
 
There is information that piperazine derivatives are being legitimately used as 
chemical intermediates, for example, in the production of detergents.  
 
4. Information from the EMEA as requested by Article 5.3 of the Decision 
 
4.1 Marketing authorisation 
 
The twenty-two Member States and two Third States which responded to the EMEA’s 
information request (see section 2.) reported that the new psychoactive substance 
BZP has not obtained a marketing authorisation. 
 
4.2 Application for a marketing authorisation 
 
The twenty-two Member States and two Third States which responded to the EMEA’s 
information request (see section 2.) reported that the new psychoactive substance 
BZP is not the subject of an application for a marketing authorisation. 
 
4.3 Suspended marketing authorisation 
 
The twenty-two Member States and two Third States which responded to the EMEA’s 
information request (see section 2.) reported that there had been no cases of a 
suspended marketing authorisation that had been granted in respect of the new 




5.1 1-benzylpiperazine was first notified via the EWS in 1999, but its emergence as a 
recreational drug with potential for rapid spread in Europe lay relatively latent until 
the second half of 2004. In the last two years, BZP-containing products are 
aggressively marketed by various retailers as a legal alternative to ecstasy, but 
clearly specified as piperazine products, often erroneously or intentionally 
misrepresented as ‘natural’ or ‘herbal’. On the illegal drugs market, BZP may also 
be sold/bought as the popular drug ecstasy. 
 
5.2 Twelve Member States and one Third State (Norway) reported to Europol and/or 
EMCDDA seizures of BZP in powder, capsule or tablets, ranging from 1 
capsule/tablet up to 64,900 tablets. 
 
5.3 There is limited information that may suggest large-scale processing and 
distribution of BZP, and a role of organised crime. One seizure of a significant 
amount of BZP suggests the involvement of organised crime in the trafficking and 
wholesale distribution of BZP. 
 




5.5 Two Member States reported on the legal importation of BZP. 
 
5.6 The total amount of seized BZP in the Member States is small when compared to 
overall ecstasy seizures in the European Union (over 15 million tablets annually 
in recent years). 
 
5.7 The marked psychoactive effects of BZP – stimulant or ecstasy-like when 
combined with TFMPP – may appeal to users and help create specific demand or 
market for BZP-containing products. This may be also due to BZP’s legal status, 
accessibility and perceived safety. All these factors may contribute to the 
establishment of BZP as a recreational drug of choice in its own right. 
 
5.8 There is some evidence about health risks related to BZP use, in particular, its 
short-term toxicity.  
 
5.9 Five Member States control 1-benzylpiperazine under drug control or equivalent 
legislation and two Member States regulate 1-benzylpiperazine under their 
medicines-related legislation. 
 
5.10 1-benzylpiperazine is currently not under assessment and has not been under 
assessment by the UN system. 
 
5.11 BZP has no known medical use (human or veterinary) in the European Union. 
There is no marketing authorisation (existing, ongoing or suspended) for 1-
benzylpiperazine in the EU or in the Member States which responded to the 
EMEA. 
 
5.12 There is no information that BZP is used for the manufacture of a medicinal 
product in Europe. However, in the absence of an EU database on the synthetic 





The health and social risks, caused by the use of, the manufacture of, and traffic in, 
BZP, as well as the involvement of organised crime and possible consequences of 
control measures, could be thoroughly assessed through a risk assessment 
























Annex 1 – Main information sources 
 









Europol–EMCDDA Joint Report 
on a new psychoactive substance: 1-benzylpiperazine (BZP) 
 
Main information sources 
 
 
1. Europol and its network of Europol National Units (ENUs) – standard reporting and 
replies to Joint Report questionnaire.  
 
2. EMCDDA and it network of National Focal Points (NFPs) – standard reporting and 
replies to Joint Report questionnaire.  
  
3. EMEA and its network of Member States’ National competent authorities (NCAs) 
responsible for human and veterinary medicinal products – replies to Joint Report 
questionnaire.  
 
4. Scientific articles published in peer reviewed journals: 
 
Austin H, Monasterio E. Acute psychosis following ingestion of 'Rapture'. 
Australas Psychiatry 2004; 12: 406-8. 
 
Balmelli C, Kupferschmidt H, Rentsch K, Schneemann M. Fatal brain edema 
after ingestion of ecstasy and benzylpiperazine M.Dtsch Med Wochenschr. 
2001 Jul 13;126(28-29):809-11.  
 
Bye C. et al. A comparison of the effects of 1-benzylpiperazine and 
dexamphetamine on human performance tests, Eur J Clin Pharmacol. 1973 
Oct; 6(3):163-9. 
 
Campbell H, Cline W, Evans M, Lloyd J, Peck AW. Comparison of the effects 
of dexamphetamine and 1-benzylpiperazine in former addicts. Eur J Clin 
Pharmacol 1973; 6: 170-176. 
 
Fantegrossi W E, Winger G, Woods J H, Woolverton W L, Coop A (2005) 
Reinforcing and discriminative stimulus effects of 1-benzylpiperazine and 
trifluoromethylphenylpiperazine in rhesus monkeys. Drug Alcohol Depend 77: 
161-8. 
 
Gee P, Richardson S, Woltersdorf W, Moore G (2005) Toxic effects of BZP-
based herbal party pills in humans: a prospective study in Christchurch, New 
Zealand. N Z Med J 118: U1784. 
 
 2 
Jones C N, Howard J L, McBennett S T (1980) Stimulus properties of 
antidepressants in the rat. Psychopharmacology 67, 111–118. 
 
Hashimoto K, Maeda H, Goromaru T. Effects of benzylpiperazine derivatives 
on the neurotoxicity of 3,4-methylenedioxymethamphetamine in rat brain 
Brain Res 1992; 590: 341-344. 
 
Klawe C, et al. A case of possible N-benzylpiperazine induced persisting   
perception disorder and description of initial intoxication syndrome, 
Pharmacopsychiatry 2001, Abstracts of the 22nd Symposium of AGNP, 
Nuremberg   2001. 
 
Kosóczky I, Grasser K, Kiszelly E, Toncsev E, Pet¨ocz L (1978) The 
antidepressant activity of a new piridincarbonic acid derivative, EGYT-475. In: 
Proceedings of the Seventh International Congress of Pharmacology, 
Abstract No. 486. Pergamon Press, Paris. 
 
Miller A A, Green A F, Young P A (1971) Unpublished work, as cited by Bye 
et al. (1973).  
 
Oberlander C, Euvrard C, Dumont C, Boissier J R (1979) Circling behavior 
induced by dopamine releasers and/or uptake inhibitors during degeneration 
of the nigrostriatal pathway. Eur. J. Pharmacol. 60, 163–170. 
 
Staack R F, Fritschi G, Maurer H H (2002) Studies on the metabolism and 
toxicological detection of the new designer drug N-benzylpiperazine in urine 
using gas chromatography-mass spectrometry. J Chromatogr B Analyt 
Technol Biomed Life Sci 773: 35-46. 
 
Tsutsumi H, Katagi M, Miki A, Shima N, Kamata T, Nakajima K, Inoue H, 
Kishi T, Tsuchihashi H (2006) Metabolism and the urinary excretion profile of 
the recently scheduled designer drug N-benzylpiperazine (BZP) in the rat. 
Journal Of Analytical Toxicology 30: 38-43. 
 
Wikstrom M, Holmgren P, Ahlner J (2004) A2 (N-benzylpiperazine) a new 
drug of abuse in Sweden. J Anal Toxicol 28: 67-70. 
 
Wilkins C, Girling M, Sweetsur P, Huckle T, Huakau J. Legal party pill use in 
New Zealand: Prevalence of use, availability, health harms and 'gateway 
effects' of benzylpiperzine (BZP) and triflourophenylmethylpiperazine 
(TFMPP) Massey University, Auckland, New Zealand. 
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Images of BZP seizures and collected samples 
 
 







Seizure on 30.06.2006 in Copenhagen – 
10 tablets, round and brown, without logo, weight 
472 mg. Content of tablets: 1% (4 mg) of BZP and 





   
 
     
 
   
 
 














               
                 
 
 
Seizure on 14.06.06, Marseille, 1 violet capsule 
with brown powder, containing also TFMPP and 
Asarone. 
Seizure on 6.09.06, Blois:  
- 4 orange capsules with white powder, containing 
also TFMPP; 
- 11 brown capsules with brown powder; 
- 1 brown capsule with grey powder containing also 
TFMPP; 
- 4 green capsules with white powder. 
 
 
Seizures in November 2006, New Caledonia 
(Oceania) several tablets and capsules of different 










Seizure on 8.09.06, Sparta (a city of  Peloponnese 
in Southern Greece), 2 bright green capsules and 
one fuchsia & black, weight 520 mg, diameter 7 
mm, logo: ‘enjoi’ (on fuchsia & black capsule). 








Seizure on 19.02.06, Paceville/St. Julians, 69 





















































Seizure in 2006 – 8 red covered tablets, containing 












Seizure in 2006 – 928 + 1305 pink tablets, logo 





















Seizure in 2004 – 1 red/white capsule, containing a 


















Seizure in March 2006 in the Burntisland area, 
Scotland, several hundred white and off-white 
diamond shaped tablets, the white ones containing 
caffeine only and the off-white ones containing 





Collected samples in 2006 – (from the Red Eye 
Frog supplier), images from TICTAC 
Communications Ltd. (c) 2006: 
 
 
- Californian Sunrise Red Eye Frog (BZP, TFMPP, 




- Strawberry Fields Red Eye Frog (BZP, TFMPP, 
Caffeine, and piperine). 
 
 
 
